Skip to content
value.today
Cleveland BioLabs logo

Cleveland BioLabs

CBLIUnlisted company
No market cap data
Compare
World rank
—
no current market cap
Revenue
$1 M
For year ending December-2021
Net income
$-102 M
-6835.6% margin
SEC filing
Employees
—

Cleveland BioLabs in brief

Cleveland BioLabs is an unlisted company in the Biotechnology industry, based in Buffalo, USA. It was founded in 2003. In the year to December 2021 it had sales of $1 M and a net loss of $102 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cleveland BioLabs

Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies.

In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma".

Cleveland BioLabs Inc. had been founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. It had license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute, and specialized in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Cleveland BioLabs timeline

6 events, 2003–2021
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2005
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2006
  6. 🔔
    Initial public offering as Cleveland Biolabs Inc
    Final prospectus filed with the SEC on 21 July 2006; shares registered for exchange trading on 20 July 2006.
  7. 2021
  8. 💰
    Record revenue of $1 million
    FY2021, the highest of the 3 years on record.
  9. ✎
    Renamed Cytocom, Inc.
    Formerly Cleveland Biolabs Inc.
  10. ✎
    Renamed Statera Biopharma, Inc.
    Formerly Cytocom, Inc..

Events of Cleveland BioLabs from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Cleveland BioLabs

Acquisitions and changes
Delisted: the exchange removed its shares from listing (Form 25-NSE) on 3 March 2023.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-6835.6%
Operating margin
-6600.0%
Return on equity
—
Liabilities / assets
107.1%
Net debt
$9M
Revenue growth
+34.2%
R&D / revenue
794.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2014: revenue —, net income $0M—FY14Fiscal year ending Dec 2015: revenue —, net income $-13M—FY15Fiscal year ending Dec 2016: revenue —, net income $-3M—FY16Fiscal year ending Dec 2017: revenue —, net income $-10M—FY17Fiscal year ending Dec 2018: revenue $1M, net income $-4M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-3M$1MFY19Fiscal year ending Dec 2020: revenue —, net income $-12M—FY20Fiscal year ending Dec 2021: revenue $1M, net income $-102M$1MFY21
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2021$1M—$-98M$-102M-6835.6%
Dec 2020——$-11M$-12M—
Dec 2019$1M-2.6%$-2M$-3M-238.7%
Dec 2018$1M—$-5M$-4M-316.7%
Dec 2017——$-6M$-10M—
Dec 2016——$-6M$-3M—
Dec 2015——$-11M$-13M—
Dec 2014——$-14M$0M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2021$-28M$0M$-28M——
Dec 2020$-5M$0M$-5M$-0.19—
Dec 2019$-3M——$-0.23—
Dec 2018$-5M——$-0.32—
Dec 2017$-7M——$-0.87—
Dec 2016$-5M——$-0.24—
Dec 2015$-12M——$-1.79—
Dec 2014$-14M——$0.60—

SEC filings

Official filings of Cleveland BioLabs with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-98 M
Net income
$-102 M

For year ending December-2021 · source: SEC filing

Balance sheet

Total assets
$21 M
Total liabilities
$23 M
Total equity
$-2 M

As of December-2021

Insider trading at Cleveland BioLabs#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
21
since
Cleveland BioLabs: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Taunia MarkvickaChief Operating Officer, DirectorGrant or award+100,000——100,000Form 4
filed Randy S. SaluckDirectorGrant or award+60,000——60,140Form 4
filed Steve K. BarbarickDirectorGrant or award+60,000——60,000Form 4
filed Lea VernyDirectorGrant or award+60,000——60,000Form 4
filed Michael K. HandleyPresident and CEO, DirectorGrant or award+296,609——296,609Form 4
filed Clifford SelskyChief Medical OfficerGrant or award+101,579——101,579Form 4
filed Robert BuckheitChief Technology OfficerGrant or award+24,378——24,378Form 4
filed Peter AronstamChief Financial OfficerGrant or award+141,370——141,370Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cleveland BioLabs#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Buybacks, Q1 2022
$0.1M
Q1 2022

Stock splits: 1-for-20 reverse split

Cleveland BioLabs share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2022Q1 2022$0.1M
Q1 2021Q1 2022$0M

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cleveland BioLabs scorecard#

Passes 0 of the 5 checks that could be worked out. Fiscal year 2021.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$102 M-$102 M in fiscal 2021 against -$3 M in 2016.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$102 MNet income -$102 M in fiscal 2021.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2021.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.37 at the end of fiscal 2021.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cleveland BioLabs: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cleveland BioLabs: statements by fiscal year
PeriodTrendFY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012
Income statement
Revenue1.50r1.1r1.1——————
Cost of revenue0.50————————
Gross profit1.00————————
Research and development125.3r1.73.65.06.57.19.72023
Selling, general and administrative—————————11
Selling and marketing0.10.0————————
General and administrative205.2r1.82.32.53.46.48.51211
Operating expenses9911r3.55.97.59.913183234
Operating income−98−11r−2.4r−4.8−5.6−6.4−11−14−23−30
Interest expense and finance costs—————00.51.3——
Share of profit of associates—————0−0.4−0.3——
Other non-operating income (expense)−3.5−1.6r−0.3r1.1−4.23.8−2.3142.97.6
Income tax0000000000
Income from continuing operations−36−12r−2.7r−3.7−9.8−2.6−130.0−20−22
Income from discontinued operations0.00————————
Net income including minority interests−102−12r−2.7r−3.7−9.8−2.6−130.0−20−22
Minority interests' share of net income−0.00r−0.0−0.1−0.10.1−0.4−1.6−2.9−4.2r
Net income attributable to shareholders−102−12r−2.6r−3.6————−17−18
Earnings per share, basic-2.90-1.66r-0.23r-0.32-0.87-0.24-1.790.60-7.67r-9.75r
Earnings per share, diluted—-0.19-0.23r-0.32-0.87-0.24-1.790.60-7.67r-0.49
Shares, weighted average (basic)357.3————————
Shares, weighted average (diluted)—12111111117.12.72.3r37
Balance sheet
Cash and cash equivalents1.80.6r1.13.64.26.95.93.11026
Short-term investments0.10r0.50.54.68.314——2.6
Receivables0.20r0.40.30.60.40.60.30.50.0
Other current assets0.80.0r0.00.10.20.30.40.20.31.1
Current assets4.10.9r2.04.59.616213.51129
Property, plant and equipment0.20.0r0.00.00.00.00.10.20.51.0
Right-of-use (leased) assets1.00.1————————
Goodwill9.30————————
Other intangible assets1.60————————
Investments in associates——————04.3——
Total assets211.0r2.04.59.616219.81532
Accounts payable4.01.1r0.30.10.20.30.21.10.81.5
Current liabilities114.6r1.1r0.92.23.15.86.56.011
Lease liabilities (non-current)0.80.1————————
Non-current liabilities———0.00.0—————
Total liabilities234.7r1.1r0.92.23.15.88.01312
Retained earnings−129−169−167r−164−160−151−148−134−136−118
Shareholders' equity−1.6−3.0−4.1r−1.52.27.59.9−1.6−9.56.3
Minority interests0.15.05.05.15.25.35.13.41114
Total equity−1.5143r−4.2r3.67.413151.81.620
Total liabilities and equity211.0r2.04.59.616219.81532
Shares outstanding351311111111112.9r2.3r45
Cash-flow statement
Depreciation and amortization—0.00.00.0——————
Share-based compensation6.12.7r——00.00.10.51.52.5
Cash from operating activities−28−5.1r−2.7−4.6−6.6−5.0−12−14r−23−21
Capital expenditure−0.2−0.0————————
Cash from investing activities13−0.0r0.24.03.95.7−10−1.80.61.4
Debt issued————————7.3—
Shares issued7.30———0279.7—16
Cash from financing activities215.7r—0.100.525117.322
Exchange-rate effect on cash—−0.00.0−0.00.1−0.20.2−1.3−0.30.5
Change in cash6.30.6r−2.5−0.6−2.71.02.8−6.9−162.8
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2022. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Cleveland BioLabs#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Delisting notice 8 · Auditor changed 3 · Debt called early 2 · Directors and officers 6 · Material agreement 9 · New debt 2 · Unregistered share sale 4 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 3

Cleveland BioLabs: events reported to the SEC
FiledWhat happenedFiling
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Material agreementNew debtUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementNew debtUnregistered share sale8-K
Delisting noticeMaterial agreement8-K
Delisting notice8-K
Auditor changed8-K/A
Delisting noticeDirectors and officersMaterial agreementUnregistered share sale8-K
Auditor changed8-K
Directors and officers8-K
Directors and officers8-K
Delisting noticeDebt called earlyMaterial agreement8-K
Directors and officers8-K
Auditor changed8-K
Delisting notice8-K/A
Delisting noticeDebt called earlyDirectors and officers8-K
Material agreement8-K
Delisting notice8-K
Material agreement8-K
Results announced8-K/A
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K/A
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Feb 1, 2023

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Cleveland BioLabs
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$2 MNo. 5Under $2 million3equity, optionsSEC
Dec 2015$1 MNo. 4Under $2 million1equitySEC
Jul 2015$25 MNo. 3$10 to $50 million1equitySEC
Jun 2014$4 MNo. 2$2 to $10 million3equity, optionsSEC
Mar 2010$5 MNo. 1$2 to $10 million9equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Cleveland BioLabs compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cleveland BioLabs🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2021
Balance sheet:
As of December-2021
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, Wikimedia Commons, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cleveland BioLabs? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cleveland BioLabs's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cleveland BioLabs? Suggest a correction